| Identification | Back Directory | [Name]
2-Furancarboxamide, N-[3-[[4-amino-6,7-di(methoxy-d3)-2-quinazolinyl]methylamino]propyl]tetrahydro- | [CAS]
1006717-31-2 | [Synonyms]
Alfuzosin-d6
2-Furancarboxamide, N-[3-[[4-amino-6,7-di(methoxy-d3)-2-quinazolinyl]methylamino]propyl]tetrahydro- | [Molecular Formula]
C19H27N5O4 | [MOL File]
1006717-31-2.mol | [Molecular Weight]
389.46 |
| Hazard Information | Back Directory | [Uses]
Alfuzosin-d6 (SL 77499-d6) is deuterium labeled Alfuzosin. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[1][2][3]. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Martin DJ, et al. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations. Life Sci. 1998;63(3):169-76. DOI:10.1016/s0024-3205(98)00257-4
[3] Wilde MI, et al. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. DOI:10.2165/00003495-199345030-00008 |
|
|